Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1991 2
1993 1
2005 1
2006 1
2007 1
2009 2
2010 2
2011 2
2012 2
2013 1
2014 4
2015 1
2017 4
2018 3
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. Fickert P, et al. J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18. J Hepatol. 2017. PMID: 28529147 Free article. Clinical Trial.
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C(23) homologue of UDCA and has shown potent anti-chole …
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical t …
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Traussnigg S, et al. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22. Lancet Gastroenterol Hepatol. 2019. PMID: 31345778 Clinical Trial.
FINDINGS: Between March 30, 2015, and Sept 20, 2016, of 198 individuals included in the analysis, 67 patients were randomly assigned to receive 500 mg norursodeoxycholic acid, 67 to 1500 mg norursodeoxycholic acid, and 64 to placebo. ...Norursodeoxy
FINDINGS: Between March 30, 2015, and Sept 20, 2016, of 198 individuals included in the analysis, 67 patients were randomly assigned to rece …
24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: A new "urso saga" on the horizon?
Chazouillères O. Chazouillères O. J Hepatol. 2017 Sep;67(3):446-447. doi: 10.1016/j.jhep.2017.06.024. Epub 2017 Jul 1. J Hepatol. 2017. PMID: 28676324 No abstract available.
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E, Eller K, Pollheimer MJ, Racedo S, Kirsch AH, Frauscher B, Wahlström A, Ståhlman M, Trauner M, Grahammer F, Huber TB, Wagner K, Rosenkranz AR, Marschall HU, Fickert P. Krones E, et al. J Hepatol. 2017 Jul;67(1):110-119. doi: 10.1016/j.jhep.2017.02.019. Epub 2017 Feb 27. J Hepatol. 2017. PMID: 28242240
We aimed to explore the therapeutic efficacy and mechanisms of norursodeoxycholic acid (norUDCA) in cholemic nephropathy. METHODS: In 8-week CBDL mice fed with norUDCA (prior or post CBDL) or chow we evaluated serum urea levels, urine cytology and urinary neutrophil …
We aimed to explore the therapeutic efficacy and mechanisms of norursodeoxycholic acid (norUDCA) in cholemic nephropathy. METH …
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. Fickert P, et al. Gastroenterology. 2006 Feb;130(2):465-81. doi: 10.1053/j.gastro.2005.10.018. Gastroenterology. 2006. PMID: 16472600
Experiments were performed to test in such mice the therapeutic effects of 24-norUrsodeoxycholic acid, a C(23) homologue of ursodeoxycholic acid with 1 fewer methylene group in its side chain. METHODS: Mdr2(-/-) mice were fed a diet containing 24-norUrsode
Experiments were performed to test in such mice the therapeutic effects of 24-norUrsodeoxycholic acid, a C(23) homologue of ur …
UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Cabrera D, Arab JP, Arrese M. Cabrera D, et al. Handb Exp Pharmacol. 2019;256:237-264. doi: 10.1007/164_2019_241. Handb Exp Pharmacol. 2019. PMID: 31236688 Review.
., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. In the present review, we summarize current experimental and clinical data regarding these BAs and its role in the treatment of certain liver dise …
., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. In the …
Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.
Buko VU, Lukivskaya OY, Naruta EE, Belonovskaya EB, Tauschel HD. Buko VU, et al. J Clin Exp Hepatol. 2014 Dec;4(4):293-301. doi: 10.1016/j.jceh.2014.02.001. Epub 2014 Feb 21. J Clin Exp Hepatol. 2014. PMID: 25755576 Free PMC article.
BACKGROUND/OBJECTIVES: Effects of norursodeoxycholic acid (norUDCA) and ursodeoxycholic acid (UDCA) on liver fibrosis progression and liver fibrosis reversal in thioacetamide (TAA)-treated rats were studied. ...
BACKGROUND/OBJECTIVES: Effects of norursodeoxycholic acid (norUDCA) and ursodeoxycholic acid (UDCA) on liver fibrosis p …
Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU, Maitz S, Wimmer R, Rust C, Invernizzi P, Ferdinandusse S, Kulik W, Fuchsbichler A, Fickert P, Trauner M, Hofmann AF, Beuers U. Denk GU, et al. Hepatology. 2010 Nov;52(5):1758-68. doi: 10.1002/hep.23911. Hepatology. 2010. PMID: 21038414
NorUDCA (24-norursodeoxycholic acid), the C₂₃-homolog of ursodeoxycholic acid (UDCA), showed remarkable therapeutic effects in cholestatic Mdr2 (Abcb4) (multidrug resistance protein 2/ATP-binding cassette b4) knockout mice with sclerosing/fibrosing cholangiti …
NorUDCA (24-norursodeoxycholic acid), the C₂₃-homolog of ursodeoxycholic acid (UDCA), showed remarkable therapeutic eff …
Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.
Blokker BA, Maijo M, Echeandia M, Galduroz M, Patterson AM, Ten A, Philo M, Schungel R, Gutierrez-de Juan V, Halilbasic E, Fuchs C, Le Gall G, Milkiewicz M, Milkiewicz P, Banales JM, Rushbrook SM, Mato JM, Trauner M, Müller M, Martínez-Chantar ML, Varela-Rey M, Beraza N. Blokker BA, et al. Hepatology. 2019 Feb;69(2):699-716. doi: 10.1002/hep.30275. Hepatology. 2019. PMID: 30229970 Free PMC article.
Sirtuin 1 (SIRT1) regulates liver regeneration and bile acid metabolism by modulating farnesoid X receptor (FXR); we here investigate its role in cholestatic liver disease. ...The effect of NorUDCA (24-norursodeoxycholic acid) was tested in BDL/SIRT(oe) mice. …
Sirtuin 1 (SIRT1) regulates liver regeneration and bile acid metabolism by modulating farnesoid X receptor (FXR); we here investigate …
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M. Halilbasic E, et al. Hepatology. 2009 Jun;49(6):1972-81. doi: 10.1002/hep.22891. Hepatology. 2009. PMID: 19475687 Free PMC article.
24-norursodeoxycholic acid (norUDCA), a side chain-modified ursodeoxycholic acid derivative, has dramatic therapeutic effects in experimental cholestasis and may be a promising agent for the treatment of cholestatic liver diseases. ...For this purpose, Mdr2(- …
24-norursodeoxycholic acid (norUDCA), a side chain-modified ursodeoxycholic acid derivative, has dramatic therapeutic e …
30 results
Jump to page
Feedback